Selegiline increases heme oxygenase-1 expression and the cytotoxicity produced by dopamine treatment of neuroblastoma SK-N-SH cells

Brazilian Journal of Medical and Biological Research

Volumn 37, Issue 7, 2004, Pages 1055-1062

  Rieder, Carlos R M ^a   Williams, A C ^b   Ramsden, D B ^b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Dopamine; Oxidative stress; Parkinson's disease; Selegiline

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; COMPLEMENTARY DNA; DOPAMINE; HEME OXYGENASE 1; HEME OXYGENASE 2; MESSENGER RNA; SELEGILINE;

ARTICLE; CELL PH; CELL STRAIN; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DNA PROBE; DOSE RESPONSE; DRUG MECHANISM; HUMAN; HUMAN CELL; INCUBATION TIME; NEUROBLASTOMA CELL; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 3543127815     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2004000700015     Document Type: Article

References (36)

1. Hirsch EC (1994). Biochemistry of Parkinson's disease with special reference to the dopaminergic systems. Molecular Neurobiology, 9: 135-142.
2. Olanow CW (1992). An introduction to the free-radical hypothesis in Parkinson's disease. Annals of Neurology, 32: S2-S9.
3. Jenner P (1994). Oxidative damage in neurodegenerative disease. Lancet, 344: 796-798.
4. Simonian NA & Coyle JT (1996). Oxidative stress in neurodegenerative diseases. Annual Review of Pharmacology and Toxicology, 36: 83-106.
5. Maines M (1988). Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB Journal, 2: 2557-2568.
6. Abraham NG, Drummond GS, Lutton JD & Kappas A (1996). The biological significance and physiological-role of heme oxygenase. Cellular Physiology and Biochemistry, 6: 129-168.
7. Shibahara S, Sato M, Muller R & Yoshida T (1989). Structural organization of the human heme oxygenase gene and the function of its promoter. European Journal of Biochemistry, 179: 557-563.
8. McCoubrey WK, Ewing JF & Maines MD (1992). Human heme oxygenase-2 - characterization and expression of a full-length cDNA and evidence suggesting that the 2 HO-2 transcripts may differ by choice of polyadenylation signal. Archives of Biochemistry and Biophysics, 295: 13-20.
9. Keyse SM & Tyrrell RM (1989). Heme oxygenase is the major 32-kDa stress protein induced in human-skin fibroblasts by UVA radiation, hydrogen-peroxide, and sodium arsenite. Proceedings of the National Academy of Sciences, USA, 86: 99-103.
10. Applegate LA, Luscher P & Tyrrell RM (1991). Induction of heme oxygenase: a general response to oxidant stress in cultured-mammalian-cells. Cancer Research, 51: 974-978.
11. Ewing J & Maines M (1991). Rapid induction of heme oxygenase 1 mRNA and protein by hyperthermia in rat brain: heme oxygenase 2 is not a heat shock protein. Proceedings of the National Academy of Sciences, USA, 88: 5364-5368.
12. Choi AMK & Alam J (1996). Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. American Journal of Respiratory Cell and Molecular Biology, 15: 9-19.
13. Castellani R, Smith MA, Richey PL, Kalaria R, Gambetti P & Perry G (1995). Evidence for oxidative stress in Pick disease and corticobasal degeneration. Brain Research, 696: 268-271.
14. Premkumar DRD, Smith MA, Richey PL, Petersen RB, Castellani R, Kutty RK, Wiggert B, Perry G & Kalaria RN (1995). Induction of heme oxygenase-1 messenger-RNA and protein in neocortex and cerebral vessels in Alzheimer's disease. Journal of Neurochemistry, 65: 1399-1402.
15. Schipper HM & Stopa EG (1995). Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. Annals of Neurology, 37: 758-768.
16. Castellani R, Smith MA, Richey PL & Perry G (1996). Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Research, 737: 195-200.
17. Schipper HM, Liberman A & Stopa EG (1998). Neural heme oxygenase-1 expression in idiopathic Parkinson's disease. Experimental Neurology, 150: 60-68.
18. Schmidt J, Mertz K & Morgan JI (1999). Regulation of heme oxygenase-1 expression by dopamine in cultured C6 glioma and primary astrocytes. Brain Research: Molecular Brain Research, 73: 50-59.
19. Berger SP, Hunger M, Yard BA, Schnuelle P & Van Der Woude FJ (2000). Dopamine induces the expression of heme oxygenase-1 by human endothelial cells in vitro. Kidney International, 58: 2314-2319.
20. Sambrook J, Fritsch EF & Maniatis T (1989). Molecular Cloning: A Laboratory Manual. 2nd edn. Cold Spring Harbor Laboratory Press, New York.
21. Moldeus P, Hogbord J & Orrenius S (1978). Isolation and use of liver cells. Methods in Enzymology, 52: 60-71.
22. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72: 248-254.
23. Kutty RK, Kutty G, Nagineni CN, Hooks JJ, Chader GJ & Wiggert B (1994). RT-PCR assay for heme oxygenase-1 and heme oxygenase-2: a sensitive method to estimate cellular oxidative damage. Annals of the New York Academy of Sciences, 738: 427-430.
24. Lai CT & Yu PH (1997). Dopamine- and L-beta-3,4-dihydroxyphenylalanine hydrochloride (L-DOPA)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells - Effects of oxidative stress and antioxidative factors. Biochemical Pharmacology, 53: 363-372.
25. Parkinson's Disease Research Group of the United Kingdom (1995). Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in Parkinson's disease. British Medical Journal, 16: 1602-1607.
26. Carrillo MC, Kitani K, Kanai S, Sato Y, Miyasaka K & Ivy GO (1994). Deprenyl increases activities of superoxide dismutase and catalase in certain brain regions in old male mice. Life Sciences, 54: 975-981.
27. Kitani K, Kanai S, Carrillo MC & Ivy GO (1994). (-)Deprenyl increases the life span as well as activities of superoxide dismutase and catalase but not of glutathione peroxidase in selective brain regions in Fischer rats. Annals of the New York Academy of Sciences, 717: 60-71.
28. Tatton WG & Chalmersredman RME (1996). Modulation of gene-expression rather than monoamine-oxidase inhibition (-)deprenyl-related compounds in controlling neurodegeneration. Neurology, 47: S171-S183.
29. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoyagid F, Jenner P & Marsden CD (1994). Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Annals of Neurology, 36: 348-355.
30. Nutter LM, Sierra EE & Ngo EO (1994). Heme oxygenase does not protect human cells against oxidant stress. Journal of Laboratory and Clinical Medicine, 123: 506-514.
31. Nath KA (1994). The functional-significance of induction of home oxygenase by oxidant stress. Journal of Laboratory and Clinical Medicine, 123: 461-463.
32. Mann VM, Cooper JM, Daniel SE, Srai K, Jenner P, Marsden CD & Schapira AHV (1994). Complex-I, iron, and ferritin in Parkinson's disease substantia nigra. Annals of Neurology, 36: 876-881.
33. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells F, Daniel S, Lees A, Jenner P & Marsden C (1991). Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain, 114: 1953-1975.
34. Connor JR & Menzies SL (1995). Cellular management of iron in the brain. Journal of the Neurological Sciences, 134: 33-44.
35. Marks GS, Brien JF, Nakatsu K & McLaughlin BE (1991). Does carbon-monoxide have a physiological-function. Trends in Pharmacological Sciences, 12: 185-188.
36. Verma A, Hirsch DJ, Glatt CE, Ronnett GV & Snyder SH (1993). Carbon-monoxide: a putative neural messenger. Science, 259: 381-384.